• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卵巢浆液性交界性肿瘤复发伴肌肉转移1例罕见病例

A Rare Case of Ovarian Serous Borderline Tumor Recurrence with Muscle Metastasis.

作者信息

Yamamura Akitoshi, Taki Mana, Kitamura Sachiko, Sunada Masumi, Yamanoi Koji, Murakami Ryusuke, Shimizu Takayoshi, Yamaguchi Ken, Hamanishi Junzo, Minamiguchi Sachiko, Mandai Masaki

机构信息

Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Department of Orthopaedic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.

出版信息

Am J Case Rep. 2025 Apr 3;26:e946680. doi: 10.12659/AJCR.946680.

DOI:10.12659/AJCR.946680
PMID:40179044
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11977427/
Abstract

BACKGROUND Ovarian serous borderline tumors (SBTs) generally have a favorable prognosis, with a very low recurrence rate. However, in rare cases, they can recur as invasive low-grade serous carcinoma (LGSC) after a prolonged follow-up period. Here, we report a case of LGSC originating from SBT that recurred 23 years after the initial surgery, with metastasis to the quadratus lumborum muscle - an exceptionally rare site of metastasis. CASE REPORT A 50-year-old woman, initially diagnosed with stage IIIC SBT and treated with complete tumor resection 23 years prior, presented with an asymptomatic recurrence detected by an elevated serum cancer antigen 125 (CA125) level. Contrast-enhanced computed tomography (CT) revealed multiple nodules suspected of peritoneal dissemination and a tumor infiltrating the quadratus lumborum muscle, suggesting recurrent SBT. A CT-guided needle biopsy confirmed that the tumor within the quadratus lumborum was a recurrence of SBT. Complete cytoreductive surgery was performed with the assistance of an orthopedic surgeon. Histopathological examination revealed progression to LGSC with cytoplasmic expression of the BRAF proto-oncogene (BRAF) V600E, indicating the presence of the BRAF V600E mutation, which is a characteristic feature of both SBT and LGSC. A retrospective review of CT images taken 10 years prior to the recurrence diagnosis showed a peritoneal tumor with calcification attached to the ileocecum, suggesting that the patient had remained asymptomatic for more than a decade after the actual onset of recurrence. CONCLUSIONS This case illustrates a rare instance of recurrent SBT with metastasis to the quadratus lumborum muscle. Given the exceptionally slow progression of recurrent SBT, long-term follow-up with CT imaging and serum CA125 monitoring is crucial for timely intervention and appropriate management upon recurrence.

摘要

背景 卵巢浆液性交界性肿瘤(SBTs)通常预后良好,复发率极低。然而,在罕见情况下,经过长时间随访后,它们可能会复发为浸润性低级别浆液性癌(LGSC)。在此,我们报告一例源自SBT的LGSC病例,该病例在初次手术后23年复发,并转移至腰方肌——一个极为罕见的转移部位。

病例报告 一名50岁女性,23年前最初被诊断为IIIC期SBT并接受了肿瘤全切手术,此次因血清癌抗原125(CA125)水平升高而检测出无症状复发。增强计算机断层扫描(CT)显示多个疑似腹膜播散的结节以及一个浸润腰方肌的肿瘤,提示SBT复发。CT引导下针吸活检证实腰方肌内的肿瘤为SBT复发。在一名骨科医生的协助下进行了完整的细胞减灭术。组织病理学检查显示进展为LGSC,伴有BRAF原癌基因(BRAF)V600E的细胞质表达,表明存在BRAF V600E突变,这是SBT和LGSC的特征性表现。对复发诊断前10年拍摄的CT图像进行回顾性分析显示,回盲部附着有钙化的腹膜肿瘤,提示患者在实际复发后十多年一直无症状。

结论 本病例说明了SBT复发并转移至腰方肌的罕见情况。鉴于复发性SBT进展异常缓慢,采用CT成像和血清CA125监测进行长期随访对于复发时的及时干预和恰当管理至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a28b/11977427/ae89f92a35f1/amjcaserep-26-e946680-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a28b/11977427/3577bfc3c18f/amjcaserep-26-e946680-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a28b/11977427/29b887af5ed1/amjcaserep-26-e946680-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a28b/11977427/b3e9d5c42a68/amjcaserep-26-e946680-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a28b/11977427/eee1f7047bf2/amjcaserep-26-e946680-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a28b/11977427/19f421ab3316/amjcaserep-26-e946680-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a28b/11977427/ae89f92a35f1/amjcaserep-26-e946680-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a28b/11977427/3577bfc3c18f/amjcaserep-26-e946680-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a28b/11977427/29b887af5ed1/amjcaserep-26-e946680-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a28b/11977427/b3e9d5c42a68/amjcaserep-26-e946680-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a28b/11977427/eee1f7047bf2/amjcaserep-26-e946680-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a28b/11977427/19f421ab3316/amjcaserep-26-e946680-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a28b/11977427/ae89f92a35f1/amjcaserep-26-e946680-g006.jpg

相似文献

1
A Rare Case of Ovarian Serous Borderline Tumor Recurrence with Muscle Metastasis.卵巢浆液性交界性肿瘤复发伴肌肉转移1例罕见病例
Am J Case Rep. 2025 Apr 3;26:e946680. doi: 10.12659/AJCR.946680.
2
Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.同期发生的卵巢浆液性交界性肿瘤和随后发生的浆液性癌的临床病理和分子特征。
Am J Surg Pathol. 2019 Nov;43(11):1462-1472. doi: 10.1097/PAS.0000000000001325.
3
Late recurrence of pStage 1 low-grade serous ovarian tumor presenting as a symptomatic bone metastasis: a case report.pStage 1期低级别浆液性卵巢肿瘤出现有症状的骨转移的晚期复发:一例报告
Diagn Pathol. 2018 Jun 30;13(1):43. doi: 10.1186/s13000-018-0720-1.
4
Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion.卵巢浆液性交界性肿瘤:137例长期随访研究,其中18例具有微乳头模式,20例有微浸润。
Am J Surg Pathol. 2002 Sep;26(9):1111-28. doi: 10.1097/00000478-200209000-00002.
5
KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.卵巢浆液性交界性肿瘤中 KRAS(而非 BRAF)突变与复发性低级别浆液性癌相关。
J Pathol. 2013 Dec;231(4):449-56. doi: 10.1002/path.4252.
6
Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma.微小浸润将卵巢浆液性交界性肿瘤与1级浸润性癌联系起来。
Gynecol Oncol. 2007 Jul;106(1):44-51. doi: 10.1016/j.ygyno.2007.01.054. Epub 2007 Apr 27.
7
Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.NRAS突变在卵巢低级别浆液性癌中是一种罕见的基因事件。
Hum Pathol. 2017 Oct;68:87-91. doi: 10.1016/j.humpath.2017.08.021. Epub 2017 Sep 2.
8
KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.原发性卵巢浆液性交界性肿瘤中的KRAS突变与肿瘤复发相关。
Virchows Arch. 2023 Jul;483(1):71-79. doi: 10.1007/s00428-023-03564-z. Epub 2023 May 23.
9
High-grade Anaplastic Transformation of Ovarian Serous Borderline Tumor: A Distinctive Morphology With Abundant Dense Eosinophilic Cytoplasm and Dismal Prognosis.卵巢浆液性交界性肿瘤高级别间变:具有丰富嗜酸性胞质和不良预后的独特形态。
Am J Surg Pathol. 2024 Nov 1;48(11):1395-1407. doi: 10.1097/PAS.0000000000002294. Epub 2024 Jul 19.
10
Early recurrence of ovarian serous borderline tumor as high-grade carcinoma: a report of two cases.卵巢浆液性交界性肿瘤早期复发为高级别癌:两例报告
Int J Gynecol Pathol. 2004 Jul;23(3):265-72. doi: 10.1097/01.pgp.0000130049.19643.f6.

本文引用的文献

1
Durable response to BRAF inhibitor monotherapy in recurrent metastatic low grade serous ovarian cancer.复发性转移性低级别浆液性卵巢癌对BRAF抑制剂单药治疗的持久反应。
Gynecol Oncol Rep. 2024 May 11;53:101412. doi: 10.1016/j.gore.2024.101412. eCollection 2024 Jun.
2
Ovarian serous borderline tumors with recurrent or extraovarian lesions: a Japanese, retrospective, multi-institutional, population-based study.伴有复发性或卵巢外病变的卵巢浆液性交界性肿瘤:一项基于日本人群的多机构回顾性研究。
Int J Clin Oncol. 2023 Oct;28(10):1411-1420. doi: 10.1007/s10147-023-02393-z. Epub 2023 Aug 1.
3
KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.
原发性卵巢浆液性交界性肿瘤中的KRAS突变与肿瘤复发相关。
Virchows Arch. 2023 Jul;483(1):71-79. doi: 10.1007/s00428-023-03564-z. Epub 2023 May 23.
4
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.贝伐珠单抗在晚期低级别浆液性卵巢癌中的疗效:MITO 22 试验数据。
Gynecol Oncol. 2023 May;172:72-77. doi: 10.1016/j.ygyno.2023.03.011. Epub 2023 Mar 23.
5
Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial.上皮性卵巢癌患者的芳香化酶抑制剂维持治疗(MATAO):一项随机、双盲、安慰剂对照、多中心 III 期临床试验研究方案。
BMC Cancer. 2022 May 6;22(1):508. doi: 10.1186/s12885-022-09555-8.
6
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.曲美替尼对比标准治疗用于复发性低级别浆液性卵巢癌患者(GOG 281/LOGS):一项国际性、随机、开放标签、多中心、2/3 期临床试验。
Lancet. 2022 Feb 5;399(10324):541-553. doi: 10.1016/S0140-6736(21)02175-9.
7
Borderline ovarian tumors: Guidelines from the French national college of obstetricians and gynecologists (CNGOF).卵巢交界性肿瘤:法国国家妇产科医师学会(CNGOF)指南
Eur J Obstet Gynecol Reprod Biol. 2021 Jan;256:492-501. doi: 10.1016/j.ejogrb.2020.11.045. Epub 2020 Nov 20.
8
Metastatic serous borderline tumor with micro-invasive ovarian carcinoma presenting as a breast lump: A case report.以乳腺肿块为表现的伴有微浸润性卵巢癌的转移性浆液性交界性肿瘤:病例报告
Medicine (Baltimore). 2020 Feb;99(9):e19383. doi: 10.1097/MD.0000000000019383.
9
-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma.- 突变的卵巢浆液性交界性肿瘤进展为浆液性癌的风险相对较低。
Oncotarget. 2019 Dec 3;10(64):6870-6878. doi: 10.18632/oncotarget.27326.
10
A Rare Case of Ovarian Serous Borderline Tumor with Brain Metastasis.一例罕见的伴有脑转移的卵巢浆液性交界性肿瘤
Case Rep Pathol. 2019 May 22;2019:2954373. doi: 10.1155/2019/2954373. eCollection 2019.